Daiju Sakurai

Prof. Dr. Daiju Sakurai

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2017 in Allergy
Verified
Journal Article
Closed access
PDF file
TITomohisa Iinuma
Tomohisa Iinuma
YOYoshitaka Okamoto
Yoshitaka Okamoto
YMY. Morimoto
Y. Morimoto
TAT. Arai
T. Arai
TST. Sakurai
T. Sakurai
TNT. Nakayama
T. Nakayama

8 March 2018 in Allergy
Verified
Journal Article
Closed access
PDF file
FIF. Ihara
F. Ihara
DSDaiju Sakurai
Daiju Sakurai
SYS. Yonekura
S. Yonekura
TITomohisa Iinuma
Tomohisa Iinuma
RYR. Yagi
R. Yagi
YOYoshitaka Okamoto
Yoshitaka Okamoto

21 June 2025 in Auris Nasus Larynx
Verified
Journal Article
Closed access
MOMitsu Okano
Mitsu Okano
KOKimihiro Okubo
Kimihiro Okubo
MGMinoru Gotoh
Minoru Gotoh
MAMikiya Asako
Mikiya Asako
NONobuo Ohta
Nobuo Ohta
TYTomokazu Yoshizaki
Tomokazu Yoshizaki

9 November 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
DSDaiju Sakurai
Daiju Sakurai
HIHiroki Ishii
Hiroki Ishii
ASAyumi Shimamura
Ayumi Shimamura
DWDaisuke Watanabe
Daisuke Watanabe
TYTakaaki Yonaga
Takaaki Yonaga
TMTomokazu Matsuoka
Tomokazu Matsuoka
The incidence of Japanese cedar pollinosis is increasing significantly in Japan, and a recent survey suggested that about 40% of the population will develop this disease. However, spontaneous remission is rare. The increased incident rate of Japanese cedar pollinosis is a huge issue in Japan. Allergen immunotherapy is the only fundamental treatment that modifies the natural course of allergic rhinitis and provides long-term remission that cannot be induced by general drug therapy. Sublingual immunotherapy for Japanese cedar pollinosis has been developed and has been covered by health insurance since 2014 in Japan. The indication for children was expanded in 2018. Clinical trials of sublingual immunotherapy for Japanese cedar pollinosis have demonstrated its long-term efficacy and safety. It is recommended for patients who wish to undergo fundamental treatment regardless of the severity of the practical guidelines for the management of allergic rhinitis in Japan. For sublingual immunotherapy, a long-term treatment period of 3 years or longer is recommended to obtain stable therapeutic effects. In recent years, evidence based on basic research and clinical trials has demonstrated sublingual immunotherapy-induced immunological changes and efficacy in patients; however, biomarkers that objectively predict and judge these therapeutic effects need to be established.

1 January 2021 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
UFUrara Funakoshi
Urara Funakoshi
SYSyuji Yonekura
Syuji Yonekura
TITomohisa Iinuma
Tomohisa Iinuma
YAYukiko Arimoto
Yukiko Arimoto
ANAtsuko Nakano
Atsuko Nakano
YOYoshitaka Okamoto
Yoshitaka Okamoto

8 March 2022 in Clinical and Experimental Dental Research
Verified
Journal Article
Open access
YKYujiro Kimura
Yujiro Kimura
KYKunio Yoshizawa
Kunio Yoshizawa
AHAsami Hotta‐Osada
Asami Hotta‐Osada
AMAkinori Moroi
Akinori Moroi
HIHiroki Ishii
Hiroki Ishii
KUKoichiro Ueki
Koichiro Ueki
Background: The purpose of this study was to evaluate the association between the immunohistochemistry (IHC) of protein tyrosine kinase 7 (PTK7) expression and clinicopathological factors of oral squamous cell carcinoma (OSCC).Methods: Tissue specimens were obtained from 80 patients with primary OSCC. IHC scoring was conducted according to the rate of positive cell and staining intensity. We used the IHC score to classify the degree of PTK7 expression and evaluate clinicopathological factors and prognosis.Results: The number of the high expression group (IHC Score 2 or 3) was 45 cases and that of the low expression group (IHC Score 0 or 1) was 35 cases. A significant difference between high expression and low expression groups was found in the N category (p = .008), degree of differentiation (p < .001), and pattern of invasion (p < .001). In accordance with the exacerbation of OSCC with respect to three parameters (N category, degree of differentiation, and pattern of invasion), the ratio of high expression of PTK7 increased. The overall 5‐year survival rate was 59.3% in the high expression group and 87.3% in the low expression group (p < .05). The pathological prognostic signs affecting overall survival were evaluated by univariate analysis and multivariate analysis with Cox proportional hazards model and showed an association with lymph node metastasis and invasion patterns.Conclusion: This study suggests that a high IHC score of PTK7 is a potential biomarker for predicting potential metastasis.